keyword
MENU ▼
Read by QxMD icon Read
search

PEG-IFN

keyword
https://www.readbyqxmd.com/read/27930338/pegylated-ifn-%C3%AE-suppresses-hepatitis-c-virus-by-promoting-the-dapk-mtor-pathway
#1
Wei-Liang Liu, Hung-Chih Yang, Ching-Sheng Hsu, Chih-Chiang Wang, Tzu-San Wang, Jia-Horng Kao, Ding-Shinn Chen
Death-associated protein kinase (DAPK) has been found to be induced by IFN, but its antiviral activity remains elusive. Therefore, we investigated whether DAPK plays a role in the pegylated IFN-α (peg-IFN-α)-induced antiviral activity against hepatitis C virus (HCV) replication. Primary human hepatocytes, Huh-7, and infectious HCV cell culture were used to study the relationship between peg-IFN-α and the DAPK-mammalian target of rapamycin (mTOR) pathways. The activation of DAPK and signaling pathways were determined using immunoblotting...
December 6, 2016: Proceedings of the National Academy of Sciences of the United States of America
https://www.readbyqxmd.com/read/27928957/long-circulating-liposomal-delivery-system-targeting-at-pdgfr-%C3%AE-enhances-the-therapeutic-effect-of-ifn-%C3%AE-on-hepatic-fibrosis
#2
Qinghua Li, Qi Yu, Jing Ju, Tiangeng You, Zhiqiang Yan, Xiangli Nan, Jie Zhong, Jing E Zhou
BACKGROUND: In this study, we developed a drug of IFN-α combined with pPB-SSLs, which specifically target at platelet-derived growth factor receptor-β (PDGFR-β). AIM: The aim of this study is to improve the limitations of IFN-α including insufficient drug concentration for the target cells and side-effects causing serious concerns in treatment of hepatic fibrosis. METHODS: We constructed the targeted stable liposomes (SSLs) that not only increase the half-life period of IFN-α, but also can deliver IFN-α to hepatic stellate cells (HSCs)...
December 8, 2016: Current Pharmaceutical Design
https://www.readbyqxmd.com/read/27927205/elimination-of-n-glycosylation-by-site-mutation-further-prolongs-the-half-life-of-ifn-%C3%AE-fc-fusion-proteins-expressed-in-pichia-pastoris
#3
Hao Jia, Yugang Guo, Xiaoping Song, Changsheng Shao, Jing Wu, Jiajia Ma, Mingyang Shi, Yuhui Miao, Rui Li, Dong Wang, Zhigang Tian, Weihua Xiao
BACKGROUND: Interferon (IFN)-α has been commonly used as an antiviral drug worldwide; however, its short half-life in circulation due to its low molecular weight and sensitivity to proteases impacts its efficacy and patient compliance. RESULTS: In this study, we present an IgG1 Fc fusion strategy to improve the circulation half-life of IFN-α. Three different forms of IgG1 Fc fragments, including the wild type, aglycosylated homodimer and aglycosylated single chain, were each fused with IFN-α and designated as IFN-α/Fc-WT, IFN-α/Fc-MD, and IFN-α/Fc-SC, respectively...
December 7, 2016: Microbial Cell Factories
https://www.readbyqxmd.com/read/27920482/hepatitis-c-virus-therapy-with-peg-interferon-and-ribavirin-in-myanmar-a-resource-constrained-country
#4
Naomi Khaing Than Hlaing, Debolina Banerjee, Robert Mitrani, Soe Htet Arker, Kyaw San Win, Nyan Lin Tun, Zaw Thant, Khin Maung Win, K Rajender Reddy
AIM: To investigate peg-interferon (peg-IFN) and ribavirin (RBV) therapy in Myanmar and to predict sustained virologic response (SVR). METHODS: This single-center, open-label, study was conducted in Myanmar between 2009 and 2014. A total of 288 patients infected with HCV genotypes 1, 2, 3 and 6 were treated with peg-IFN alpha-2a (180 μg/wk) or alpha-2b (50 to 100 μg as a weight-based dose) and RBV as a weight-based dose (15 mg/kg/d). Treatment duration was 48 wk for genotypes 1 and 6, 24 wk for genotype 2, and 24 or 48 wk for genotype 3 based on rapid virologic response (RVR)...
November 21, 2016: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/27904617/the-interferon-lambda-4-rs368234815-predicts-treatment-response-to-pegylated-interferon-alpha-and-ribavirin-in-hemophilic-patients-with-chronic-hepatitis-c
#5
Maryam Keshvari, Seyed Moayed Alavian, Bita Behnava, Ali Pouryasin, Heidar Sharafi
BACKGROUND: A dinucleotide variant rs368234815 in interferon lambda 4 (IFNL4) gene was recently found to be associated with the hepatitis C virus (HCV) treatment response. This study aimed to assess the impact of IFNL4 rs368234815 polymorphism on treatment response to pegylated-IFN alpha (Peg-IFN-α) and ribavirin (RBV) in hemophilic patients with chronic hepatitis C (CHC). MATERIALS AND METHODS: In this retrospective study, 92 hemophilic patients with CHC who were treated with Peg-IFN-α/RBV were investigated...
2016: Journal of Research in Medical Sciences: the Official Journal of Isfahan University of Medical Sciences
https://www.readbyqxmd.com/read/27882162/evaluation-of-the-health-related-quality-of-life-using-the-36-item-short-form-health-survey-in-patients-with-chronic-hepatitis-c-receiving-pegylated-interferon-ribavirin-telaprevir-triple-treatment
#6
Mitsuyuki Suzuki, Toru Ishikawa, Ai Sakuma, Satoshi Abe, Hiroko Abe, Fujiko Koyama, Tomomi Nakano, Aya Ueki, Hirohito Noguchi, Erina Hasegawa, Shiori Yamagata, Miki Kobayashi, Kazutaka Ohashi, Hiroshi Hirosawa, Takako Fukazawa, Yuka Maruyama, Toshiaki Yoshida
The rate of sustained virologic response (SVR) has increased in patients with chronic hepatitis C (CHC; genotype 1) since triple treatment with pegylated interferon (PEG-IFN), ribavirin (RBV) and telaprevir (TVR) was included in Japanese health insurance. However, side effects such as high-grade anemia and skin disorders means it is important to investigate the extent to which quality of life (QOL) is maintained during treatment. The impact on health-related (HR) QOL, as a result of TVR-based triple treatment was investigated long-term (48 weeks) in 34 patients (18 men, 16 women) following TVR-based triple treatment, using the 36-item short form health survey (SF-36)...
November 2016: Experimental and Therapeutic Medicine
https://www.readbyqxmd.com/read/27842532/silybin-supplementation-during-hcv-therapy-with-pegylated-interferon-%C3%AE-plus-ribavirin-reduces-depression-and-anxiety-and-increases-work-ability
#7
Giulia Malaguarnera, Gaetano Bertino, Giuseppe Chisari, Massimo Motta, Michele Vecchio, Marco Vacante, Filippo Caraci, Carmela Greco, Filippo Drago, Giuseppe Nunnari, Michele Malaguarnera
BACKGROUND: Hepatitis C virus infection and interferon treatment are often associated with anxiety, depressive symptoms and poor health-related quality of life. To evaluate the Silybin-vitamin E-phospholipids complex effect on work ability and whether health related factors (anxiety and depression) were associated with work ability in subjects with chronic hepatitis C treated with Pegylated-Interferon-α2b (Peg-IFN) and Ribavirin (RBV). METHODS: Thirty-one patients (Group A) with chronic hepatitis and other 31 subjects in Group B were recruited in a randomized, prospective, placebo controlled, double blind clinical trial...
November 15, 2016: BMC Psychiatry
https://www.readbyqxmd.com/read/27822709/itpa-polymorphism-effects-on-decrease-of-hemoglobin-during-sofosbuvir-and-ribavirin-combination-treatment-for-chronic-hepatitis-c
#8
Kei Morio, Michio Imamura, Yoshiiku Kawakami, Takashi Nakahara, Yuko Nagaoki, Tomokazu Kawaoka, Masataka Tsuge, Akira Hiramatsu, Hiroshi Aikata, Clair Nelson Hayes, Grace Naswa Makokha, Hidenori Ochi, Hajime Amano, Keiko Arataki, Takashi Moriya, Hiroyuki Ito, Keiji Tsuji, Hiroshi Kohno, Koji Waki, Toru Tamura, Toshio Nakamura, Kazuaki Chayama
BACKGROUND: Polymorphisms in the inosine triphosphatase (ITPA) gene is associated with anemia induced by peg-interferon (PEG-IFN) plus ribavirin (RBV) treatment for patients with chronic hepatitis C virus (HCV) infection. However, the effect of ITPA polymorphism on sofosbuvir plus RBV treatment is unknown. METHODS: Two hundred and forty-four patients with chronic HCV genotype 2 infection without decompensated liver cirrhosis were treated with sofosbuvir plus RBV for 12 weeks...
November 7, 2016: Journal of Gastroenterology
https://www.readbyqxmd.com/read/27799299/arabinoxylan-rice-bran-biobran-suppresses-the-viremia-level-in-patients-with-chronic-hcv-infection-a-randomized-trial
#9
Hosny Salama, Eman Medhat, Magda Shaheen, Abdel-Rahman N Zekri, Tarneem Darwish, Mamdooh Ghoneum
Current treatments for Hepatitis C virus (HCV) have severe side effects and are very expensive. There is a need to explore effective natural therapies against HCV that are less toxic and more cost-effective. In the current study, 37 chronic HCV patients were randomized into two groups and treated with either pegylated interferon (PEG IFN) plus ribavirin (n = 21) or Biobran, an arabinoxylan from rice bran (1 g/day) (n = 16). We examined viremia, liver enzymes, interferon-γ (IFN-γ) levels in serum, and toxicity before and three months after treatment...
October 31, 2016: International Journal of Immunopathology and Pharmacology
https://www.readbyqxmd.com/read/27793564/role-of-hbsag-decline-in-patients-with-chronic-hepatitis-b-hbeag-negative-and-e-genotype-treated-with-pegylated-interferon
#10
Lucio Boglione, Jessica Cusato, Giuseppe Cariti, Giovanni Di Perri, Antonio D'Avolio
Treatment options for patients with chronic hepatitis B (CHB) and hepatitis B e antigen (HBeAg)-negative are pegylated interferon alfa-2a (PEG-IFN) for 48 weeks or nucleos(t)ide analogues (NAs). The choice of patients with higher chance of sustained response (SR) to PEG-IFN can be made with pre-treatment and on-treatment factors; recent studies evidenced the role of early drop of serum hepatitis B surface antigen (HBsAg) as predictor of SR. The aim of this study was the evaluation of early decrease of HBsAg on the SR in HBeAg-negative patients with E genotype...
October 26, 2016: Antiviral Research
https://www.readbyqxmd.com/read/27790789/simeprevir-plus-sofosbuvir-for-eight-or-12-weeks-in-treatment-na%C3%A3-ve-and-treatment-experienced-hepatitis-c-virus-genotype-4-patients-with-or-without-cirrhosis
#11
M El Raziky, M Gamil, M K Ashour, E A Sameea, W Doss, Y Hamada, G Van Dooren, R DeMasi, S Keim, I Lonjon-Domanec, R Hammad, M S Hashim, M Hassany, I Waked
The OSIRIS study investigated efficacy and safety of simeprevir plus sofosbuvir for eight or 12 weeks in hepatitis C virus (HCV) genotype 4-infected patients with METAVIR F0-F4 fibrosis. Sixty-three patients (33 treatment-naïve and 30 peg-interferon/ribavirin (Peg-IFN/RBV)-experienced) enrolled in a partly randomized, open-label, multicentre, phase IIa study. Patients with F0-F3 fibrosis were randomized (1:1) into two groups (A1 and A2), stratified according to treatment experience and METAVIR score, to receive either eight weeks (Group A1, n=20) or 12 weeks (Group A2, n=20) of treatment...
October 27, 2016: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/27775635/polymorphisms-of-hla-dm-on-treatment-response-to-interferon-ribavirin-in-patients-with-chronic-hepatitis-c-virus-type-1-infection
#12
Hongbo Chen, Yinan Yao, Yifan Wang, Hua Zhou, Tianxiang Xu, Jing Liu, Guocheng Wang, Yongfeng Zhang, Xiang Chen, Qingwei Liu, Peng Huang, Rongbin Yu
BACKGROUND: HLA-DM gene, which is related to antigen processing and presentation and located in the non-classical class-II region of human leukocyte antigen (HLA) region, may play a crucial role in chronic hepatitis C virus (HCV) infection treatment outcomes. The study was conducted to evaluate the role of the variant of several single nucleotide polymorphisms (SNPs) in HLA-DM gene in HCV treatment outcomes. METHODS: We genotyped four SNPs from the candidate genes (HLA-DMA and DMB) in 336 patients who were treated with pegylated interferon-alpha and ribavirin (PEG IFN-α/RBV)...
October 20, 2016: International Journal of Environmental Research and Public Health
https://www.readbyqxmd.com/read/27761441/hepatitis-b-progress-in-understanding-chronicity-the-innate-immune-response-and-cccdna-protection
#13
REVIEW
Kenichi Morikawa, Tomoe Shimazaki, Rei Takeda, Takaaki Izumi, Machiko Umumura, Naoya Sakamoto
Hepatitis B virus (HBV) infection is a serious health threat around the world. Despite the availability of an effective hepatitis B vaccine, the number of HBV carriers is estimated to be as high as 240 million worldwide. Global mortality due to HBV-related liver diseases such as chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma (HCC) may be as high as 1 million deaths per year. HBV is transmitted via blood and body fluids, and is much more infectious than both human immunodeficiency virus (HIV) and hepatitis C virus...
September 2016: Annals of Translational Medicine
https://www.readbyqxmd.com/read/27757504/network-meta-analysis-of-first-and-second-generation-protease-inhibitors-for-chronic-hepatitis-c-genotype-1-efficacy-based-on-rvr-and-svr-24
#14
Helena H Borba, Astrid Wiens, Laiza M Steimbach, Cassio M Perlin, Fernanda S Tonin, Maria L A Pedroso, Fernando Fernandez-Llimos, Roberto Pontarolo
PURPOSE: This study aimed to compare the efficacy among direct-acting antiviral agents (first and second-generation direct-acting antiviral agents (DAAs)) with placebo and with standard dual therapy (pegylated interferon + ribavirin (Peg-IFN + RBV)) in terms of rapid virologic response (RVR) and sustained virologic response (SVR) in chronic hepatitis C genotype 1 treatment. METHODS: We performed a systematic review of randomized controlled trials (RCTs) in MEDLINE, International Pharmaceutical Abstracts, Cochrane Library, SCIELO, and Scopus and conducted a network meta-analysis to compare the efficacy of boceprevir (BOC), daclatasvir (DCV), grazoprevir, simeprevir (SMV) and telaprevir (TVR), in treatment-naive and treatment-experienced patients...
October 19, 2016: European Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/27750229/efficacy-and-safety-of-sofosbuvir-plus-ribavirin-treatment-for-patients-with-chronic-hepatitis-c-genotype-2
#15
Kayo Sugimoto, Soo Ki Kim, Soo Ryang Kim, Mana Kobayashi, Airi Kato, Eri Morimoto, Susumu Imoto, Chi Wan Kim, Yasuhito Tanaka, Masatoshi Kudo, Yoshihiko Yano, Yoshitake Hayashi
OBJECTIVES: The efficacy of sofosbuvir plus ribavirin (RBV) treatment for hepatitis C virus (HCV) genotype 2 focusing on virological response was compared with that of pegylated interferon (peg-IFN) plus RBV treatment. Safety of the former focusing on the decline in hemoglobin levels was compared with that of the latter and assessed in terms of age and inosine triphosphatase (ITPA). METHODS: Patients (n = 17) receiving sofosbuvir plus RBV and those (n = 24) receiving peg-IFN plus RBV diagnosed with chronic HCV genotype 2 were enrolled in this study, and the efficacy and safety of both treatments were assessed...
2016: Digestive Diseases
https://www.readbyqxmd.com/read/27749916/antiviral-treatment-of-hcv-infected-patients-with-b-cell-non-hodgkin-lymphoma-anrs-hc-13-lympho-c-study
#16
Laurent Alric, Caroline Besson, Nathanael Lapidus, Juliette Jeannel, Jean-Marie Michot, Patrice Cacoub, Danielle Canioni, Stanislas Pol, Frédéric Davi, Pascaline Rabiega, Loic Ysebaert, Delphine Bonnet, Olivier Hermine
: Hepatitis C virus (HCV) infection is associated with lymphoproliferative disorders and B-cell non-Hodgkin lymphomas (B-NHLs). Evaluation of the efficacy and safety profiles of different antiviral therapies in HCV patients with B-NHL is warranted. METHODS: First, we evaluated the sustained virologic response (SVR) and safety of Peg-interferon-alpha (Peg-IFN) + ribavirin +/- first protease inhibitors (PI1s) therapy in 61 HCV patients with B-NHL enrolled in a nationwide observational survey compared with 94 matched HCV-infected controls without B-NHL...
2016: PloS One
https://www.readbyqxmd.com/read/27748564/the-impact-of-hepatitis-c-virus-outside-the-liver-evidence-from-asia
#17
REVIEW
Zobair M Younossi, Atsushi Tanaka, Yuichiro Eguchi, Young-Suk Lim, Ming-Lung Yu, Norifumi Kawada, Yock Young Dan, Craig Brooks-Rooney, Francesco Negro, Mario U Mondelli
Between 80 and 115 million people worldwide are chronically infected with hepatitis C virus, with 60%-90% of these being undiagnosed. Untreated chronic hepatitis C (CHC) is associated with progressive liver disease, cirrhosis, hepatocellular carcinoma and liver-related mortality. A number of extrahepatic manifestations are also reported in CHC patients, further adding to the burden of the disease. CHC also impacts patients in terms of lower health-related quality of life, higher levels of fatigue and reduced productivity...
October 17, 2016: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/27728965/clinical-characteristics-and-treatment-outcome-of-peginterferon-plus-ribavirin-in-patients-infected-with-genotype-6-hepatitis-c-virus-in-korea-a-multicenter-study
#18
Su Rin Shin, Young Seok Kim, Young-Seok Lim, June Sung Lee, Jin Woo Lee, Sun Myung Kim, Sook-Hyang Jeong, Joo Hyun Sohn, Myung Seok Lee, Sang Hoon Park
Background/Aims: Because of the limited geographic distribution, there have been insufficient data regarding hepatitis C virus (HCV) genotype 6 in Korea. This study aimed to investigate the clinical characteristics and available treatment outcomes of patients with genotype 6 HCV in Korea. Methods: From 2004 to 2014, data were collected from Korean patients infected with genotype 6 HCV in eight hospitals. Results: Thirty-two patients had genotype 6 HCV...
October 13, 2016: Gut and Liver
https://www.readbyqxmd.com/read/27680223/a-case-of-chronic-inflammatory-demyelinating-polyradiculoneuropathy-after-treatment-with-pegylated-interferon-%C3%AE-2a-in-a-patient-with-chronic-hepatitis-b-virus-infection
#19
Hiroyuki Naito, Ikuko Takeda, Akiko Segawa, Masataka Tsuge, Hirofumi Maruyama, Masayasu Matsumoto
We report the case of a 42-year-old man with chronic hepatitis B virus infection who developed weakness and paresthesia in the extremities 2 months after administration of pegylated interferon (Peg-IFN)α-2a. Nerve conduction studies conducted 6 months after onset showed abnormal temporal dispersions in both tibial nerves. We diagnosed chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) resulting from treatment with Peg-IFNα-2a. Neurological symptoms were prolonged despite suspension of the treatment...
September 28, 2016: Rinshō Shinkeigaku, Clinical Neurology
https://www.readbyqxmd.com/read/27667784/treatment-of-eosinophilic-otitis-media-with-pegylated-interferon-%C3%AE-2a-and-2b
#20
Brian A Neff, Stephen G Voss, Matthew L Carlson, Erin K O'Brien, Joseph H Butterfield
OBJECTIVE/HYPOTHESIS: Eosinophilic otitis media (EOM) is a variant of chronic otitis media that is characterized by the development of thick mucoid middle ear effusion, adult onset bronchial asthma, sinonasal polyposis, and aspirin sensitivity. EOM is typically refractory to corticosteroid therapy and surgical intervention. Pegylated interferon (PEG-IFN) has effectively treated hypereosinophilic syndrome in clinical trials; however, the efficacy of this medication for EOM treatment remains undefined...
September 26, 2016: Laryngoscope
keyword
keyword
31627
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"